Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of MN…
Clarivate Epidemiology's coverage of membranous nephropathy comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…
Clarivate Epidemiology’s coverage of sarcoidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of AD…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…